The Trump Administration's effort to move cannabis from Schedule I to Schedule III of the Controlled Substances Act is now facing legal challenges on two fronts - a federal appellate court and a DEA administrative hearing - and the outcome of either could directly reshape the regulatory and tax environment for licensed cannabis operators across the country. Three petitions challenging the Department of Justice's April 22 Order have been consolidated before the D.C. Circuit Court of Appeals. Meanwhile, a separate DEA hearing on broader cannabis rescheduling opened June 29 and is scheduled to wrap by July 15.
For dispensary operators, multi-state operators, and cannabis brands tracking this closely, the stakes are not abstract. Rescheduling to Schedule III would remove cannabis businesses from the reach of Internal Revenue Code Section 280E - the tax provision that bars plant-touching companies from deducting ordinary business expenses, a burden that effectively taxes gross profit rather than net income and has squeezed margins across licensed retail since the Obama era. Resources like indicaonline.com have documented how operators in state-legal markets continue to absorb these costs even as their businesses operate in full compliance with state law. A rescheduling that survives judicial review would represent the single largest financial relief event in the history of licensed cannabis retail - which is precisely why the legal challenges now pending in the D.C. Circuit matter so much.
The DOJ's April 22 Order took an unconventional path to get here. Rather than following the CSA's standard rescheduling procedure - which requires notice-and-comment rulemaking and an administrative hearing - Acting Attorney General Todd Blanche invoked Section 811(d)(1), a treaty-implementation provision that allows the Attorney General to bypass ordinary procedures when necessary to fulfill U.S. obligations under international drug-control conventions, specifically the 1961 Single Convention on Narcotic Drugs. The practical effect was speed: the Order moved FDA-approved cannabis products and state-licensed medical cannabis to Schedule III immediately, without the multi-year administrative process that has historically defined federal drug scheduling. That's the tradeoff. Faster relief, but a narrower legal foundation - and one the petitioners are now attacking directly.
What the Petitioners Are Actually Arguing
Three separate petitions - filed by anti-legalization group Smart Approaches to Marijuana and drug-testing trade group NDASA, by a coalition of states including Indiana and Nebraska, and by a group that includes substance-abuse treatment providers, physicians, and pharmaceutical developer MMJ International Holdings - were consolidated by the D.C. Circuit on May 29. Louisiana, initially part of the second petition, has since withdrawn.
The core legal argument runs like this: Section 811(d)(1) was designed for a narrow purpose - keeping U.S. scheduling consistent with treaty obligations - and does not give the Attorney General authority to move cannabis below Schedule II absent a clear treaty mandate. The petitioners lean heavily on the D.C. Circuit's 1977 ruling in NORML v. DEA, 559 F.2d 735, which interpreted the treaty provision in limited terms. They also argue the Order creates what they call a "hybrid" regulatory regime - placing certain cannabis products in Schedule III while retaining controls ordinarily reserved for Schedule I or II substances, including production quotas and import-export restrictions. The argument, essentially, is that Congress never authorized that kind of regulatory mixing, and the DOJ exceeded its authority by attempting it.
On June 9, NDASA and MMJ jointly moved to stay the Order pending judicial review. The government filed its response on July 2. The stay question is the one to watch right now. If the D.C. Circuit grants it, the Order goes on hold - and with it, the new DEA registration pathway for qualifying medical cannabis operators and the 280E relief that Schedule III status would otherwise provide. Operators who have already begun adjusting financial projections based on expected 280E relief should be accounting for that risk in their planning.
The DEA Hearing and Its Contested Record
The administrative hearing running parallel to the D.C. Circuit litigation covers broader ground: whether cannabis generally - including adult-use cannabis - should be transferred to Schedule III. The hearing follows an earlier rescheduling proceeding initiated under the Biden administration that stalled amid procedural disputes and allegations of improper ex parte communications between DEA officials and anti-legalization advocates. That history matters, because it shapes how closely any resulting administrative record will be scrutinized.
The current hearing has already generated its own controversy. On June 18, the DEA announced that all seven parties selected to participate oppose rescheduling - including SAM, NDASA, a coalition of states, the Tennessee Bureau of Investigation, DUID Victim Voices, and two physicians. No pro-rescheduling participant was admitted. The DEA's reasoning: supporters of rescheduling had not demonstrated they were "adversely affected or aggrieved" by the proposed rule, the threshold required under DEA regulations for "interested person" status. Industry groups and legalization advocates pushed back hard, arguing that excluding rescheduling proponents produces an incomplete administrative record - one that could be vulnerable to judicial challenge later. An administrative law judge rejected reconsideration requests, including one from NORML, on June 24.
Here's the wrinkle, though: the DEA itself is technically the proponent of the proposed rule. In its opening statement on June 29, the agency confirmed its support for moving cannabis to Schedule III and indicated it would present testimony from an FDA scientist and a pain physician addressing cannabis's accepted medical use. So the hearing is not as one-sided as the participant list suggests. What remains to be seen is whether the administrative record built through this process - with no formally admitted advocates for rescheduling - will hold up if and when the recommendation reaches federal court review.
What Licensed Operators Should Be Tracking
For cannabis retailers, wholesalers, and compliance professionals, the near-term calendar is tight. The DEA hearing was scheduled to conclude by July 15. The D.C. Circuit's ruling on the stay motion - whenever it arrives - will be the first concrete signal of how the appellate court views the DOJ's legal authority under Section 811(d)(1).
The practical implications break down along a few lines:
- 280E tax exposure: If the stay is granted and the Order is placed on hold, plant-touching businesses remain subject to 280E - meaning no deduction for cost of goods beyond production costs, no write-offs for payroll, rent, POS systems, or compliance infrastructure. Every month the Order remains in legal limbo is another month of inflated effective tax rates.
- DEA registration: The Order created a new registration pathway for state-licensed medical cannabis operators seeking to operate under federal Schedule III status. A stay would pause that pathway pending the court's final ruling.
- Compliance posture: State-level obligations - seed-to-sale tracking, METRC reporting, compliant packaging, lab testing, COA documentation - remain entirely unchanged by the federal proceedings. State licensing requirements do not pause for federal litigation.
- Broader rescheduling timeline: Even if the DOJ's Order survives the D.C. Circuit challenge, the DEA's administrative hearing addresses a different question - whether all cannabis, including adult-use, should move to Schedule III. That process, and whatever comes out of it, faces its own potential legal review.
To put it plainly: rescheduling is not done. It may not be close to done. The Administration moved faster than any prior administration on this question, but speed and durability are different things. What licensed operators need right now is contingency planning - financial modeling that accounts for both a world where 280E relief materializes and one where federal litigation delays it for another year or more. The two proceedings now running simultaneously will determine which world arrives first.
